Hopp til hovedinnhold

Nevromyelitis optica spectrum disorders (NMOSD)

Sist revidert:
Sist revidert av:
  1. Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol. 2020 Nov;31(6):462-468. doi: 10.1097/ICU.0000000000000703. PMID: 33009077; PMCID: PMC7771018.
  2. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501. PMID: 32670177 PubMed  
  3. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89 . pmid:26092914 PubMed  
  4. Ikeguchi R, Shimizu Y, Shimomura A, Suzuki M, Shimoji K, Motohashi T, Yamamoto T, Shibata N, Kitagawa K. Paraneoplastic AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma: A Case Report and Literature Review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 20;8(5):e1045. PMID: 34285095 PubMed  
  5. Cai G, He D, Chu L, Dai Q, Xu Z, Zhang Y. Paraneoplastic neuromyelitis optica spectrum disorders: three new cases and a review of the literature. Int J Neurosci. 2015 Aug 20:1-9 . pmid:26010208 PubMed  
  6. Kitley J1, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, Palace J, Vincent A.. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 ; 18;79(12):: 1273-7. pmid:22914827 PubMed  
  7. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016;79(2):206–216. PMID: 26537743 PubMed  
  8. Siritho S, Nopsopon T, Pongpirul K. Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. 2020 Oct 10. doi: 10.1007/s00415-020-10257-z. Epub ahead of print. PMID: 33037886. PubMed  
  9. Bennett JL. Optic Neuritis. Continuum (Minneap Minn). 2019 Oct;25(5):1236-1264. doi: 10.1212/CON.0000000000000768. PMID: 31584536 PubMed  
  10. Juryńczyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):20-5. doi: 10.1136/jnnp-2014-308984. Epub 2014 Sep 23. PMID: 25248365. PubMed  
  11. Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol. 2021 Jan;20(1):60-67. PMID: 33186537. PubMed  
  12. Holmøy T, Høglund RA, Illes Z, Myhr KM, Torkildsen Ø. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol. 2020 Oct 3. doi: 10.1007/s00415-020-10235-5. Epub ahead of print. PMID: 33011853 PubMed  
  13. Chen L, Qiu W, Lu J, Zhao C, Quan C. Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors. J Neurol Neurosurg Psychiatry. 2020 Nov 20;92(1):53–61. doi: 10.1136/jnnp-2020-323982. Epub ahead of print. PMID: 33219038; PMCID: PMC7803904.
  14. Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020. pmid:32199095 PubMed  
  15. Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. . pmid:26194198 PubMed  
  16. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008 Nov;65(11):1443-8. doi: 10.1001/archneur.65.11.noc80069. Epub 2008 Sep 8. PMID: 18779415. PubMed  
  17. Kim SH, Jeong IH, Hyun JW, Joung A, Jo HJ, Hwang SH, Yun S, Joo J, Kim HJ. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. JAMA Neurol. 2015 Sep 1;72(9):989-95 . pmid:26167726 PubMed  
  18. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013 Sep 1;70(9):1110-7. doi: 10.1001/jamaneurol.2013.3071. PMID: 23897062.
  19. Kim SH, Kim Y, Kim G, Park NY, Jang HM, Shin HJ, Hyun JW, Kim HJ. Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):486-487. PMID: 29929977 PubMed  
  20. Mealy MA, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014; 71(3): 324-30. pmid:24445513 PubMed  
  21. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-66. Neurology  
  22. Jacob A. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analyses of 24 patients. Arch Neurol 2009; 66: 1128-33.
  23. Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, Kim HJ.. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.. JAMA Neurol 2014; Nov;71(11):: 1372-8. pmid:25199960 PubMed  
  24. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D; Aegis of French National Observatory of Multiple Sclerosis. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry. 2013 May;84(5):511-6. doi: 10.1136/jnnp-2012-303121. Epub 2012 Nov 8. PMID: 23138769. PubMed  
  25. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):918-21. doi: 10.1136/jnnp-2012-304774. Epub 2013 Mar 6. PMID: 23467418. PubMed  
  26. Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. Neurology. 2019 Oct 29;93(18):e1732-e1741. doi: 10.1212/WNL.0000000000008394. Epub 2019 Oct 2. PMID: 31578302 PubMed  
  27. Kessler RA, Mealy MA, Levy M.. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder.. Neurol Neuroimmunol Neuroinflamm. 2016 Jul 28;3(5):e269 .
  28. Kim SH, Jang H, Park NY, Kim Y, Kim SY, Lee MY, Hyun JW, Kim HJ. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 23;8(2):e947. doi: 10.1212/NXI.0000000000000947. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2021 Apr 19;8(4): PMID: 33622675; PMCID: PMC7903808.
  29. i R, Li C, Huang Q, Liu Z, Chen J, Zhang B, Liu C, Shu Y, Wang Y, Kermode AG, Qiu W. Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation. Eur J Neurol. 2022 Sep;29(9):2792-2800. doi: 10.1111/ene.15425. Epub 2022 Jun 11. PMID: 35638372. PubMed  
  30. Kim SH, Huh SY, Jang H, Park NY, Kim Y, Jung JY, Lee MY, Hyun JW, Kim HJ. Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. Eur J Neurol. 2020 Aug;27(8):1546-1555. doi: 10.1111/ene.14274. Epub 2020 May 25. PMID: 32320109.
  31. Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, Leite MI, Jarius S, Hellwig K. Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol. 2020 Mar;16(3):154-170. doi: 10.1038/s41582-020-0313-y. Epub 2020 Feb 20. PMID: 32080393.
  32. Wang L, Zhou L, ZhangBao J, Huang W, Chang X, Lu C, Wang M, Li W, Xia J, Li X, Chen L, Qiu W, Lu J, Zhao C, Quan C. Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors. J Neurol Neurosurg Psychiatry. 2020 Nov 20;92(1):53–61. doi: 10.1136/jnnp-2020-323982. Epub ahead of print. PMID: 33219038; PMCID: PMC7803904.
  33. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, Küker W, Chandratre S, Vincent A, Palace J.. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.. JAMA Neurol. 2014 ; Mar;71(3): 276-83. pmid:24425068 PubMed  
  34. van Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol. 2015 Nov 22 . pmid:26593750 PubMed  
  35. Wang L, Tan H, Huang W, Chang X, ZhangBao J, Zhou L, Lu C, Wang M, Lu J, Zhao C, Quan C. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies. Eur J Neurol. 2022 Apr;29(4):1128-1135. PMID: 34967093. PubMed  
  36. Lauenstein AS1, Stettner M, Kieseier BC, Lensch E.. Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.. BMJ Case Rep. ; Mar 26: 2014 . pmid:24671322 PubMed  
  37. Tanaka M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol 2009; 62: 167-70.
  • Hanne Marie Bøe Lunde, spesialist i nevrologi PhD
  • Lars Bø, spesialist i nevrologi, professor dr med
  • Unn Ljøstad, spesialist i nevrologi, professor PhD
  • Åse Mygland, spesialist i nevrologi, professor dr med

Tidligere fagmedarbeidere

  • Trygve Holmøy, spesialist i nevrologi, professor dr med
  • Kjell Morten Myhr, spesialist i nevrologi, professor dr med